Acute Febrile Neutrophilic Dermatosis Market
Number of pages: 100 | Report Format: PDF | Published date: March 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
6.7% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Drug Class, Route of Administration, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global acute febrile neutrophilic dermatosis market is expected to grow at a revenue CAGR of 6.7% from 2023 to 2031.
Acute Febrile Neutrophilic Dermatosis Market Fundamentals
Acute febrile neutrophilic dermatosis syndrome, also known as Sweet Syndrome or Gomm Button disease, is characterized by erythematous plaques and papules and constitutional symptoms, such as fever and malaise. It is linked to several underlying conditions, such as infections, cancer, inflammatory bowel disease, autoimmune disorders, pregnancy, and medications. Acute febrile neutrophilic dermatosis can be either classical or idiopathic, cancer-related, or drug-induced. Each eventually leads to uninvited neutrophil proliferation or persistence in the blood and tissue, which is accountable for the disease’s clinical symptoms.
Acute febrile neutrophilic dermatosis is most common in middle-aged women but can afflict males, children (occasionally), and the elderly. It has been discovered to be more frequent in those with the genetic marker HLA-B54. Acute febrile neutrophilic dermatosis can strike previously healthy people; however, it is more commonly associated with an acute systemic infection or an underlying chronic disease. The risk factors associated with this syndrome are sunlight exposure, infection of the upper respiratory tract (e.g., chest infection, streptococcal throat infection), irritable bowel disease, rheumatoid arthritis, lupus erythematosus, and recurrent polychondritis. Blood illnesses, such as leukemia (most often acute myelogenous leukemia or myelodysplastic syndromes), also exist.
Acute Febrile Neutrophilic Dermatosis Market Dynamics
Although acute febrile neutrophilic dermatosis syndrome is a rare condition, the prevalence of the disease is increasing globally. This increase in prevalence is driving the demand for acute febrile neutrophilic dermatosis syndrome treatment. Advances in diagnostic techniques, such as genetic testing and molecular diagnostics, have improved the accuracy of diagnosis of acute febrile neutrophilic dermatosis syndrome, leading to increased diagnosis rates and demand for treatment. The availability of effective treatments, such as corticosteroids and other immunosuppressive drugs, is driving the revenue growth of the acute febrile neutrophilic dermatosis syndrome treatment market. These medications can help manage the symptoms of the condition and improve the quality of life for patients. With the increase in healthcare expenditure globally, there has been an increase in funding for research and development of new treatments for rare diseases like Sweet syndrome. This also drives the revenue growth of the acute febrile neutrophilic dermatosis syndrome treatment market. There is a great opportunity for the development of this market due to increasing awareness of acute febrile neutrophilic dermatosis syndrome among physicians and patients, contributing to the revenue growth of the treatment market. With more awareness, patients are more likely to seek treatment, and physicians are more likely to diagnose the condition, leading to increased demand for treatment options.
However, a lack of knowledge of the main cause of acute febrile neutrophilic dermatosis is resulting in limitations in the management treatment. Additionally, stringent regulatory policies and a lack of awareness among people are likely to restrain and further impede the market’s revenue growth rate.
Acute Febrile Neutrophilic Dermatosis Market Ecosystem
The global acute febrile neutrophilic dermatosis syndrome has been analyzed from five perspectives: type, drug class, route of administration, distribution channel, and region.
Acute Febrile Neutrophilic Dermatosis Market by Type
[467867]
Based on type, the global acute febrile neutrophilic dermatosis market can be further segmented into classical (or idiopathic) sweet syndrome, malignancy-associated sweet syndrome, and drug-induced Sweet syndrome.
The classical sweet syndrome segment dominates the global acute febrile neutrophilic dermatosis market with the largest revenue share due to the large patient base and the high occurrence of classical/idiopathic sweet syndrome among the population. Clinical symptoms and physical features characterize classical Sweet’s syndrome, and pathologic findings include pyrexia, an elevated neutrophil count, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate composed primarily of mature neutrophils in the upper dermis. Symptoms and clinical signs usually improve rapidly after starting systemic corticosteroid medication. Systemic corticosteroids are the basis of treatment for this type of syndrome. Dapsone has been used either alone or in conjunction with other medications. Potassium iodide, colchicine, Indomethacin, clofazimine, cyclosporine, and antibiotics are also utilized.
Acute Febrile Neutrophilic Dermatosis Market by Drug Class
Based on drug class, the global acute febrile neutrophilic dermatosis market can be further segmented into anti-inflammatory, immunosuppressants, anti-infectives, and others.
The anti-inflammatory drugs segment dominates the global market with the largest revenue share. It is expected to retain its dominance during the forecast time due to a large number of sales. These anti-inflammatory drugs are commonly used to treat the symptoms of acute febrile neutrophilic dermatosis syndrome because they help to reduce inflammation in the body. Additionally, these drugs are the primary treatment option for managing the symptoms of acute febrile neutrophilic dermatosis syndrome. These drugs work by reducing the production of inflammatory chemicals in the body, which helps to alleviate pain, swelling, and redness in the affected areas. Several anti-inflammatory drugs treat acute febrile neutrophilic dermatosis syndrome, including nonsteroidal anti-inflammatory drugs, corticosteroids, and immune-suppressing medications. These drugs can be administered orally or topically, depending on the severity of the symptoms.
Acute Febrile Neutrophilic Dermatosis Market by Route of Administration
Based on the route of administration, the global acute febrile neutrophilic dermatosis market can be further segmented into oral, topical, and parenteral.
The oral administration of drugs as the treatment for acute febrile neutrophilic dermatosis Syndrome segment accounts for the largest revenue share in the global market. Oral drugs are easier to administer than other forms of medication, such as topical and parenteral. Patients benefit from administrating the pills or capsules alone without needing regular healthcare visits for treatment procedures. Additionally, oral drugs can have systemic effects, as they can work throughout the body. Oral drugs are effective in treating acute febrile neutrophilic dermatosis syndrome. They can target the underlying causes of inflammation and/or bacterial infection. Moreover, some patients may prefer oral medications over other forms of treatment because they are familiar with taking pills and feel more comfortable with this route of administration.
The topical segment is estimated to show rapid revenue growth in CAGR during the projected timeframe. Topical treatments are applied directly to the affected skin and can be formulated as creams, lotions, gels, ointments, or sprays. These products can help to reduce inflammation, relieve itching and redness, and moisturize the skin to prevent dryness and flakiness. Topical treatments for this medical condition may include corticosteroids, emollients, and antihistamines. Corticosteroids are anti-inflammatory agents that can help to reduce swelling and redness. Many patients prefer topical treatments because they are easy to use, convenient, and generally well-tolerated. They can be applied directly to the affected skin area, and the risk of systemic side effects is usually low. Additionally, topical treatments are available in various strengths and formulations, allowing healthcare providers to tailor therapy to each patient’s individual needs. These factors contribute to the segment’s growth, thereby propelling the global acute febrile neutrophilic dermatosis market.
Acute Febrile Neutrophilic Dermatosis Market by Distribution Channel
Based on the distribution channel, the global acute febrile neutrophilic dermatosis market can be further segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies play a key role in treating acute febrile neutrophilic dermatosis syndrome and are important contributors to the revenue growth of the acute febrile neutrophilic dermatosis market. Several of the advantages of hospital pharmacy contribute to the market’s expansion. Hospital pharmacies can provide patients with a greater range of medications, including biologics, that may not be available in other settings. This can help ensure that patients receive the best possible treatment for their conditions. Additionally, hospital pharmacies can work closely with other healthcare professionals to provide coordinated and tailored care for acute febrile neutrophilic dermatosis syndrome patients. This can result in better treatment outcomes and patient satisfaction. These pharmacies may guide patients about their medications and how to properly consume them, boosting medication adherence and minimizing the risk of poor effects. In addition, the hospital pharmacy may monitor patients’ medications and assist with side effects and other problems that may arise throughout therapy. This can help to ensure that patients receive the best care available and that treatment outcomes improve. These pharmacies can also participate in clinical trials and other acute febrile neutrophilic dermatosis syndrome-related research activities. This can aid in developing new drugs and therapies for the ailment, benefiting patients and boosting market revenue growth.
Acute Febrile Neutrophilic Dermatosis Market by Region
Based on the region, the global acute febrile neutrophilic dermatosis market can be further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America leads the acute febrile neutrophilic dermatosis market in terms of revenue, and this trend is projected to continue during the forecast period. The revenue growth of the market in this region can be due to the presence of many significant market participants. Additionally, the region’s high disposable income has expedited the revenue growth of the healthcare sector due to the ability to invest in highly complicated medicine that satisfies the particular medical demands of the people, further driving market expansion in the region.
Asia Pacific is predicted to be a developing market over the forecast period. The growth in the number of government programs to raise public awareness about the causes and symptoms of acute febrile neutrophilic dermatosis syndrome encourages market expansion in the region.
Acute Febrile Neutrophilic Dermatosis Market Competitive Landscape
The prominent players operating in the global acute febrile neutrophilic dermatosis market are:
Takeda Pharmaceuticals Inc., Jacobus Pharmaceutical Company Inc., and Mayne Pharma Group Limited are among the key players in the global acute febrile neutrophilic dermatosis market.
The classical/idiopathic sweet syndrome segment dominates the global acute febrile neutrophilic dermatosis market.
Asia Pacific is expected to observe the highest revenue growth in the global acute febrile neutrophilic dermatosis market during the forecast period.
Lack of awareness among the population is one of the major restraining factors to the revenue growth of the global market.
Acute febrile neutrophilic dermatosis is characterized by a constellation of clinical symptoms, physical features, and pathologic findings, including fever, neutrophilia, and tender erythematous skin lesions (papules, nodules, and plaques), and diffuse infiltrate composed primarily of mature neutrophils located in the upper dermis.
*Insights on financial performance are subject to the availability of information in the public domain